Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

Inclusion Criteria: 1. The first six patients will be ages \>12 years old and \<35 years old. Thereafter in a second stage, patients ages 2 to 50 years old will be included. 2. Patient with a matched related donor or who has a related haploidentical donor identified. 3. Performance score of at least 70 by Karnofsky or 0 to 1 by ECOG (age \> 12 years), or Zubrod or Lansky Play Performance Scale of at least 70 (age \<12 years). 4. Adequate major organ system function as demonstrated by: 1. Serum creatinine clearance equal or more than 50 ml/min (calculated with Cockroft-Gault formula). 2. Bilirubin equal or less than 1.5 mg/dl except for Gilbert's disease. ALT and/or AST equal or less than 3x institutional ULN. Conjugated (direct) bilirubin less than 2x upper limit of normal. 3. Left ventricular ejection fraction equal or greater than 50%. 4. Diffusing capacity for carbon monoxide (DLCO) equal or greater than 50% 5. Predicted, corrected for hemoglobin. For children \< 7 years of age who are unable to perform PFT, oxygen saturation \> 92% on room air by pulse oximetry. 5. Patient or the patient's legal representative, parent(s) or guardian should be able to provide written informed consent. Assent of a minor if participant's age is at least seven and less than eighteen years. 6. Sexually active males and females of childbearing potential must agree to use a form of contraception considered effective and medically acceptable by the Investigator. Exclusion Criteria: 1. HIV positive; active hepatitis B or C. 2. Uncontrolled infections. 3. Liver cirrhosis. However mild fibrosis will be allowed i.e. fine reticulin or Grade 1, with bridging fibrosis. 4. CNS involvement within 3 months. 5. Positive pregnancy test in a woman with child bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization. 6. Inability to comply with medical therapy or follow-up. 7. Will restrict eligibility to a maximum BMI of ≤40 8. Patient with a known history of allergic reactions to any constituents of the cell product, including a known history of allergic reactions to DMSO. 9. Prior allo-SCT 10. Other active malignancy/cancer diagnosis in remission for at least 2yrs. Malignancies not being excluded are as follows: Ductal carcinoma in situ (DCIS), Basal cell carcinoma (BCC), Cervical intraepithelial neoplasia (CIN)